10:00 , Apr 18, 2019 |  BC Extra  |  Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to...
00:47 , Mar 2, 2019 |  BC Extra  |  Company News

Emerging company roundup: Anthos, Maze, Oyster Point

In a week that had at least four companies post venture raises north of $80 million, Maze Therapeutics and Anthos Therapeutics Inc. had the biggest hauls, with financings near or above $200 million. Blackstone partnered...
20:11 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
19:38 , Feb 27, 2019 |  BC Extra  |  Company News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
19:47 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...
22:40 , Dec 19, 2018 |  BC Extra  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Wednesday that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon is...
23:05 , Oct 5, 2018 |  BioCentury  |  Finance

Risk-sharing at scale

By operating under the Blackstone umbrella, Clarus Ventures will be able to significantly scale up its risk-sharing investment strategy. On Oct. 4, private equity firm Blackstone announced plans to acquire Clarus for undisclosed terms. Clarus...
20:17 , Oct 5, 2018 |  BC Week In Review  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
20:14 , Oct 4, 2018 |  BC Extra  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...